<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="179129">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00763009</url>
  </required_header>
  <id_info>
    <org_study_id>02-202-1</org_study_id>
    <secondary_id>A-13147.1</secondary_id>
    <nct_id>NCT00763009</nct_id>
  </id_info>
  <brief_title>Persantine: Variation in Response Trial</brief_title>
  <official_title>Persantine: Variation in Response Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UConn Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>UConn Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to understand why different people respond
      differently to the medication Persantine. The effects of Persantine will be evaluated by
      performing echocardiograms, blood tests and by measuring the flow of blood in the arteries
      of the heart in patients undergoing a clinically indicated percutaneous coronary
      intervention.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will receive three doses of Persantine intravenously for the research study.
      Before and after receiving the Persantine doses, patients will have an echocardiogram and
      coronary artery blood flow will be measured. Blood tests,measure the function of the
      adenosine transporter. In addition variations in the gene for the adenosine transporter will
      be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Limited numbers of patients qualified for trial
  </why_stopped>
  <start_date>September 2002</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine if there is a subgroup of patients that have an abnormal adenosine transporter expression, or abnormal adenosine transporter protein function.</measure>
    <time_frame>6-12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the clinical significance of variations in adenosine transfer function on coronary flow.</measure>
    <time_frame>6-12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>All subjects receive dipyridamole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>There is only a single arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dipyridamole</intervention_name>
    <description>0.28mg/kg over 4 minutes intravenously x three doses; totalling 0.84mg/kg intravenously</description>
    <arm_group_label>All subjects receive dipyridamole</arm_group_label>
    <other_name>Persantine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients &gt; 21 years old

          -  Patient undergoing cardiac catheterization with planned PTCA or with a significant
             coronary lesion of either the LAD or Circumflex

        Exclusion Criteria:

          -  Theophylline or oral Persantine use in 24hrs

          -  Second or third degree AV block, or sick sinus syndrome without a functioning
             pacemaker

          -  Active asthma or bronchospasm

          -  Patients with severe hepatic insufficiency

          -  Patients experiencing an acute transmural infarction at the time of the index visit

          -  Conditions that are known to affect resistive vessel function or myocardial flow
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael A Azrin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Connecticut</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruce T Liang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Connecticut</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCONN Health Center</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 8, 2012</lastchanged_date>
  <firstreceived_date>September 24, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Connecticut Health Center</investigator_affiliation>
    <investigator_full_name>Michael A. Azrin</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dipyridamole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
